# MOTS-c peptide: The Mitochondrial-Derived Metabolic Regulator, Read Study by Study > MOTS-c peptide is a 16-amino-acid mitochondrial-derived peptide that activates AMPK and improves glucose handling in animal models. An editorial digest of the literature, every quantitative claim cited. A study-by-study reading of the published record — the founding 2015 discovery, the exercise-mimetic and nuclear-signaling findings, and the human-data gap stated plainly. Every quantitative claim is cited. ## The gist The MOTS-c peptide is a tiny protein your own mitochondria make. Mitochondria are the parts of a cell that turn food into usable energy, and MOTS-c is a 16-letter message encoded inside their DNA. In animal studies, giving extra MOTS-c improved how the body handles sugar, helped prevent weight gain on a high-fat diet, and made older mice physically stronger. Those are striking results — but almost all of them are in mice and cells. There are no completed human trials showing it works as a treatment. This site reads the actual studies, plainly, and marks where the evidence stops. ## What Is MOTS-c? MOTS-c peptide is a 16-amino-acid peptide — sequence MRWQEMGYIFYPRKLR — encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1) [1]. That origin makes it a *mitochondrial-derived peptide* (a small protein written into the mitochondrion's own DNA rather than the cell's nuclear genome), one of a handful of such peptides discovered over the past two decades. It is not a synthetic invention. MOTS-c is endogenous — your cells already produce it, and it is detectable in human plasma and skeletal muscle. Its levels rise with exercise and shift with age and metabolic state [2][4]. The molecule, weighing 2174.61 Da, is highly conserved across mammals, which is part of why researchers took an interest: a sequence that evolution has preserved tends to be doing something useful. The founding 2015 paper in *Cell Metabolism* established the headline mechanism. MOTS-c inhibits the folate cycle (a set of chemical reactions cells use to build the components of DNA), which causes a molecule called AICAR to accumulate, which in turn switches on AMPK — AMP-activated protein kinase, the enzyme a cell uses as its low-fuel sensor [1]. When AMPK turns on, the cell shifts toward burning fuel and pulling in glucose. In mice, that translated to better insulin sensitivity and resistance to diet-induced obesity. ## What the MOTS-c Literature Has Demonstrated Across the published record, three findings stand out for their clarity. First: MOTS-c administration prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice, with skeletal muscle identified as the primary target organ [1]. Second: exercise induces the body's own MOTS-c, and giving it to mice significantly enhanced physical performance — treadmill capacity improved in aged animals at P=0.000002 [2]. Third: under metabolic stress, MOTS-c physically travels from the mitochondrion into the nucleus to change which genes are switched on [3] — the first demonstrated case of a mitochondrial-encoded peptide doing that. The more recent literature has sharpened the mechanism. A 2024 study in *iScience* identified casein kinase 2 (CK2) — a constantly-active signalling enzyme — as a direct binding target of MOTS-c, and showed the peptide tunes CK2 differently in muscle versus fat [13]. A 2025 rat study reported that MOTS-c restored mitochondrial respiration in a type-2-diabetic heart and was associated with lower fasting glucose [15]. And on the human side, a 2024 multicenter cohort found that circulating MOTS-c independently tracked mortality and cardiovascular risk in chronic hemodialysis patients — among the strongest human-association data the peptide has [14]. The full mechanism is laid out on the [MOTS-c mechanism of action](/research) page, and the metabolic and aging findings — the part of the literature this digest leans into — are collected under [MOTS-c metabolic research](/metabolic-research). ## What Does the MOTS-c Peptide Do? ### What Does the MOTS-c Peptide Do? MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Its best-characterized action is inhibiting the folate cycle and de novo purine biosynthesis, which raises AICAR and activates AMPK — improving glucose handling and insulin sensitivity mainly in skeletal muscle in animal studies [1]. Under stress it also moves into the nucleus to regulate gene expression [3]. ### What Is MOTS-c Peptide Used For? In the research literature MOTS-c is studied for metabolic regulation (glucose and insulin handling), as a candidate exercise-mimetic, and within aging biology [1][2][4]. It has no approved clinical use. There are no completed human efficacy trials; the human evidence to date is observational biomarker data, not interventional outcomes. ## Where This Site Draws the Line Search demand for MOTS-c is large — tens of thousands of queries a month — and it vastly outruns the strength of the clinical evidence. That gap is the reason this digest exists. Every efficacy claim you will read here is qualified by the species it came from. Rodent doses are reported as "studied at X mg/kg in mice," never as guidance. There is no validated human dose, no measured human half-life, and no approved formulation [4]. That caution is not skepticism about the science — the founding mechanism is well-replicated and the recent work is genuinely interesting. It is precision about *what kind* of evidence exists. "Improved insulin sensitivity in mice" and "associated with lower mortality in a 94-patient cohort" are real findings worth reading; "a treatment proven to work in people" is a claim the literature does not yet support. This site keeps those statements separate, on purpose. MOTS-c is also not a dietary supplement and not an FDA-approved drug; it is handled as a research chemical, and it is named on an FDA advisory-committee agenda for evaluation. The full picture — including the FDA framework and anti-doping context — is on the [MOTS-c legal status and 503A category](/legal-status) page. For dosing in the research context and the [MOTS-c half-life and pharmacokinetics](/dosage), see the dosage page; for the rest, the [frequently asked questions about MOTS-c](/faq) and the [full reference list](/references) collect the sources. --- An exhibition-wall reading of the mitochondrial-derived MOTS-c peptide literature — each study hung as its own plate and cited, the large search demand held apart from the empty human-trial wall, and the FDA research-only standing and July-2026 PCAC agenda noted before anything else; no clinic curates this room and nothing here is dispensed or sold.